ZLABのチャート
ZLABの企業情報
| symbol | ZLAB |
|---|---|
| 会社名 | Zai Lab Ltd （ザイ・ラボ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Zai Lab Ltd incorporated on March 28 2017 is a biopharmaceutical company. The Company is focused on discovering or licensing developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market including in the fields of oncology autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306) Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101) ZL-2302 and ZL-1101. ザイ・ラボはケイマン諸島籍のバイオ医薬品企業。主に腫瘍、自己免疫、感染症の治療に向けた医薬品の開発・商業化に従事する。同社はTesaro社と共同で、経口タイプの上皮卵巣がんの治療薬「Zejula」を米国で販売する。中国市場において医療ニ―ズの高い分野で治療法の発見やライセンス供与に取り組む。本社は中国・上海市。 Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide. |
| 本社所在地 | 4560 Jinke Road Bldg. 1 Fourth Floor Pudong Shanghai 201210 CHN |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +86 21-6163-2588 |
| 設立年月日 | 41334 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 88人 |
| url | www.zailaboratory.com |
| nasdaq_url | https://www.nasdaq.com/symbol/zlab |
| adr_tso | 11562969 |
| EBITDA | EBITDA（百万ドル） -67.07543 |
| 終値（lastsale） | 17.41 |
| 時価総額（marketcap） | 201311290.29 |
| 時価総額 | 時価総額（百万ドル） 868.68320 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 691.72338 |
| 当期純利益 | 当期純利益（百万ドル） -67.45513 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Zai Lab Ltd revenues was not reported. Net loss totaled to $41.5M. Results are not comparable due to year end change. |
ZLABのテクニカル分析
ZLABのニュース
TRVN, ZLAB and BRFS are among pre market gainers 2023/05/31 12:20:18 Seeking Alpha
WANG & LEE GROUP (WLGS) +45%. Marker Therapeutics (MRKR) +37% Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells.LL Flooring Holdings…
Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today 2023/05/22 15:11:09 The Motley Fool
Several Chinese stocks rose today after positive sentiment from Wall Street and recent comments made by President Biden.
Zai Lab gets priority review for lung cancer dug repotrectinib in China 2023/05/18 12:50:29 Seeking Alpha
China''s National Medical Products Administration ((NMPA)) granted priority review to Zai Lab''s (ZLAB) repotrectinib for a type of lung cancer. Read more here
Zai Lab Limited (ZLAB) Q1 2023 Earnings Call Transcript 2023/05/10 18:08:07 Seeking Alpha
Zai Lab Limited. (NASDAQ:NASDAQ:ZLAB) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ETCompany ParticipantsBilly Cho - Chief Financial OfficerSamantha Du - Founder, Chairperson and…
Zai Lab: Q1 Earnings Insights 2023/05/09 21:56:52 Benzinga
Zai Lab (NASDAQ: ZLAB ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM. Here''s what investors need to know about the announcement. Earnings Zai Lab beat estimated earnings by 46.32%, reporting an EPS of $-0.51 versus an … Full story available on Benzinga.com
Relieved Of ''High-Risk'' Marker, New Horizon Health Aims To Break Even Next Year 2023/03/20 13:08:49 Benzinga
Key Takeaways: New Horizon Health is expected to attract more investors after becoming the seventh Hong Kong biotech stock to shed a designation reserved for high-risk stocks The company’s gross margin has climbed to 84.5% and is expected to remain at 85% to 90% going forward By Molly Wen The China market for early-screening cancer products has grown rapidly in recent years, fueled by the country’s huge cancer caseload and a growing middle class that can afford such services.One major beneficiary of that boom is New Horizon Health Ltd. (6606.HK), whose latest results released last week show its revenue more than tripled to 765 million yuan ($110.8 million) last year. Equally significant, the report also showed the company’s adjusted loss last year narrowed by 59.6% to 100 million yuan. Its improving financial health didn’t end there. The company also said its application to remove the “B” marker from its ticker, which designates high risk stocks, was approved and took effect on March 20.
Karuna/ Zai Lab succeed in late-stage trial for schizophrenia candidate (NASDAQ:KRTX) 2023/03/20 11:17:23 Seeking Alpha
Karuna Therapeutics (KRTX) announced Monday that its lead asset KarXT co-developed with Zai Lab (ZLAB), reached the main goal in a Phase 3 trial for schizophrenia. Read the full story here.
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia 2023/03/20 10:35:00 GlobeNewswire
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001)
Collapse of Silicon Valley Bank Has Chinese Startups Worried 2023/03/17 23:13:44 Voice of America News
The collapse of Silicon Valley Bank has caused panic not just in the U.S. tech industry but also in China, where the bank has been a key player for years among Chinese startups. In recent days, many startups in China have issued statements to reassure their investors that their deposits with SVB will not impact their operations. Before the bank failed and was taken over by U.S. regulators this month, Silicon Valley Bank was the 16th-largest American bank. In foreign markets, SVB’s reputation for financing about half of all U.S. venture-backed technology and health care companies made it a popular choice for companies, including those based in China and backed by U.S. venture capitalists. BeiGene, one of China''s largest biotech companies that specializes in the development of cancer drugs, said that the collapse of SVB would have “no major impact” on its operations, and that its uninsured cash deposits in Silicon Valley Bank totaled only $175 million, or about 3.9% of its cash and other investments.
Zai Lab Sees Profits On The Horizon As Commercialization Accelerates 2023/03/13 12:00:00 Seeking Alpha
Zai Lab is set to reach several product milestones this year, as at least eight new products are on track for approval by the end of 2025. Find out more here.
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) 2022/12/05 23:10:00 GlobeNewswire
SHANGHAI and CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the company’s partner Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company reported preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRAS G12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the potential tolerability and feasibility of a concurrent combination regimen of a KRAS G12C inhibitor and a PD-1/L1 checkpoint inhibitor.
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking 2022/12/05 23:10:00 businessfortnight.com
Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutation Findings will be presented on December 7 at […] The post Zai Lab Partner Mirati Therapeutics Presents Late-Breaking appeared first on Businessfortnight .
Have you been able to find a good deal on Zai Lab Limited’s shares? 2022/12/01 16:48:00 US Post News
The share price of Zai Lab Limited (NASDAQ:ZLAB) rose to $38.56 per share on Wednesday from $33.69. While Zai Lab Limited has overperformed by 14.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZLAB fell by -44.32%, with highs and lows ranging from $74.22 to $20.98, […]
Chinese Stocks Are Surging Today: What''s Going On? 2022/11/29 20:15:09 Benzinga
Shares of several Chinese companies are trading higher Tuesday amid hopes that protests in China could spark an easing of COVID restrictions . Here''s a look at some of the names charging higher. Alibaba Group Holding Ltd (NYSE: BABA ) Li Auto Inc (NASDAQ: LI ) Tencent Music Entertainment Group (NYSE: TME ) GDS Holdings Ltd (NASDAQ: GDS ) Lufax Holding Ltd (NYSE: LU ) Zai Lab Ltd (NASDAQ: ZLAB ) KANZHUN Ltd (NASDAQ: BZ ) Futu Holdings … Full story available on Benzinga.com